卡培他滨联合奥沙利铂化疗方案治疗Ⅲ期结肠癌的近期疗效及对患者T淋巴细胞水平的影响  

Short-term efficacy of chemotherapy regimen of capecitabine combined with oxaliplatin in the treatment of stageⅢcolon cancer and its influence on T lymphocytes levels

作　　者：王璐[1] 叶威[1] 查亚云 WANG Lu;YEWei;CHAYayun(Department of Oncology,Jiujiang NO.1 People's Hospital,Jiujiang,Jiangxi,332000,China)

机构地区：[1]九江市第一人民医院肿瘤科,江西九江332000

出　　处：《当代医学》2023年第17期47-50,共4页Contemporary Medicine

摘　　要：目的探究卡培他滨联合奥沙利铂化疗方案治疗Ⅲ期结肠癌的近期疗效及对患者T淋巴细胞水平的影响。方法选取2018年1月至2020年12月本院收治的68例Ⅲ期结肠癌患者作为研究对象,随机分为常规组与联合组,每组34例。常规组采用奥沙利铂化疗方案,联合组采用卡培他滨联合奥沙利铂化疗方案,比较两组近期疗效、生存率、不良反应发生率及T淋巴细胞水平[白细胞介素(IL)-2、肿瘤坏死因子-α(TNF-α)、IL-4、IL-10]。结果联合组治疗总有效率为82.35%,高于常规组的58.82%,差异有统计学意义(P<0.05)。联合组2年生存率为64.71%,高于常规组的47.06%,但差异无统计学意义;联合组3年生存率为38.24%,高于常规组的14.71%,差异有统计学意义(P<0.05)。联合组不良反应发生率为8.82%,低于常规组的23.53%,但差异无统计学意义。治疗后,联合组IL-2水平、Th1/Th2[(11.24±2.71)ng/L、(7.42±1.81)%]均高于常规组[(7.85±1.79)ng/L、(6.02±1.34)%],TNF-α、IL-4、IL-10水平[(86.65±4.89)、(11.12±2.18)、(18.39±2.75)ng/L]均低于常规组[(98.08±5.93)、(14.93±2.25)、(20.92±3.88)ng/L],差异有统计学意义(P<0.05)。结论与常规治疗方案相比,卡培他滨联合奥沙利铂化疗方案近期疗效更佳,患者远期生存率更高,耐受性更好,且可显著增强患者免疫能力,安全有效,值得临床推广应用。Objective To explore the short-term efficacy of chemotherapy regimen of capecitabine combined with oxaliplatin in the treatment of stageⅢcolon cancer and its influence on T lymphocytes levels.Methods 68 patients with stageⅢcolon cancer admitted to the hospital from January 2018 to December 2020 were selected as the research subjects,and they were randomly divided into the conventional group and the combined group,with 34 cases in each group.The conventional group was treated with oxaliplatin chemotherapy regimen while the combined group was given chemotherapy regimen of capecitabine combined with oxaliplatin,the short-term efficacy,survival rate,incidence rates of adverse reactions and levels of T lymphocytes[interleukin(IL)-2,tumor necrosis factor-α(TNF-α),IL-4,IL-10]were compared between the two groups.Results The total effective rate of treatment in the combined group was 82.35%,which was higher than 58.82%in the conventional group,and the difference was statistically significant(P<0.05).The 2-year survival rate in the combined group was 64.71%,which was higher than 47.06%in the conventional group,but the difference was not statistically significant.The 3-year survival rate in the combined group was 38.24%,which was higher than 14.71%in the conventional group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the combined group was 8.82%,which was lower than 23.53%in the conventional group,but the difference was not statistically significant.After treatment,the levels of IL-2 and Th1/Th2 in the combined group([11.24±2.71]ng/L,[7.42±1.81]%were higher than those in the conventional group([7.85±1.79]ng/L,[6.02±1.34]%),the levels of TNF-α,IL-4 and IL-10([86.65±4.89],[11.12±2.18],[18.39±2.75]ng/L)were lower than those in the conventional group([98.08±5.93],[14.93±2.25],[20.92±3.88]ng/L),and the differences were statistically significant(P<0.05).Conclusion Compared with conventional treatment regimen,chemotherapy regimen of capecitabine combined with oxali

关 键 词：卡培他滨 奥沙利铂 Ⅲ期结肠癌 近期疗效 T淋巴细胞 

分 类 号：R735.35[医药卫生—肿瘤]